Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Ascendis Pharma A/S at Bank of America Merrill Lynch Health Care Conference Transcript

May 14, 2019 / 04:20PM GMT
Release Date Price: $120.28 (+2.48%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

The senior biotech analyst here at Bank of America Merrill Lynch. It's our pleasure to introduce Ascendis this morning. Speaking for Ascendis, sitting next to me, is Jan Mikkelsen, Chief Executive Officer; and sitting next to him is Scott Smith, Chief Financial Officer and Chief Strategist of the company.

This will be a Q&A session. Feel free to ask any questions that you might have. And maybe we can kick it off, Jan, with the recent data that you presented for growth hormone deficiency. So if you can give us a 2-minute summary of Ascendis and what's happening and maybe start off by focusing on GHD and then we can go from there.

Jan MÃ;ller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive Director

¸ - /- -

First, thanks a lot, Tazeen. It's a pleasure to be here. And also this is one of the first opportunities we have really to go out to a conference after our Phase III heiGHt data. So it's fair

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot